Logo image of VANI

VIVANI MEDICAL INC (VANI) Stock News

NASDAQ:VANI - Nasdaq - US92854B1098 - Common Stock - Currency: USD

1.17  +0.02 (+1.74%)

After market: 1.19 +0.02 (+1.71%)

VANI Latest News, Press Relases and Analysis

News Image
9 days ago - Zacks Investment Research

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.

Mentions: ANGO CVS ITGR

News Image
a month ago - Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study...

News Image
a month ago - Vivani Medical, Inc.

Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical...

News Image
10 months ago - BusinessInsider

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vivani Medical (NASDAQ:VANI) just reported results for the second quarter of 20...

News Image
10 months ago - InvestorPlace

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.

News Image
2 months ago - Vivani Medical, Inc.

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam...

News Image
2 months ago - Vivani Medical, Inc.

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and...

News Image
2 months ago - Yahoo Finance

Do You Believe in Columbus McKinnon Corp.’s (CMCO) Compelling Risk/Reward Opportunity?

Heartland Advisors, an investment management company, released its “Heartland Value Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund was down 5.63% in the first quarter compared to a 7.74% fall for the Russell 2000 Value Index. The fund outperformed the benchmark over the past 1, 3, […]

Mentions: CMCO CHWY KR HON ...

News Image
2 months ago - Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects...

News Image
3 months ago - Vivani Medical, Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once...

News Image
3 months ago - Stocktwits

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.

Mentions: VTI VXF

News Image
3 months ago - Vivani Medical, Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide...